Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Statement regarding Elektron Technology plc

17 Jun 2014 07:00

RNS Number : 7602J
Microgen PLC
17 June 2014
 

microgen

www.microgen.com

 

17 June 2014

 

 

 

STATEMENT REGARDING ELEKTRON TECHNOLOGY PLC

 

Announcement falling under Rule 2.8 of the City Code on Takeovers and Mergers (the "Code")

 

Microgen plc ("Microgen") announced its interest in exploring opportunities consistent with the Elektron Technology plc ("Elektron") Strategic Alternatives Process ("SAP") on 20 May 2014 and provided a further update on 27 May 2014.

 

Microgen submitted its original proposal to the Board of Elektron on 2 May 2014 ("Refinancing Proposal"). The Refinancing Proposal indicated, subject to due diligence information being provided and other terms typical of a transaction of this nature, that Microgen could make a potential equity-based investment of between £12 million and £18 million and that Elektron would remain listed on AIM. Further information in respect of this proposal was detailed in Microgen's announcement of 20 May 2014.

 

The Refinancing Proposal was rejected by the Board of Elektron on 7 May 2014 who also then advised that, contrary to the SAP announcement, only offers for the entire issued share capital of Elektron would be considered. Following Microgen's announcement of 20 May 2014, access to due diligence information was progressed allowing Microgen to determine whether or not it was able to submit such an offer.

 

Whilst Microgen's preferred structure remains the Refinancing Proposal, on 11 June 2014 Microgen submitted to the Board of Elektron a non-binding letter with details of a potential offer by Microgen for the entire issued share capital of Elektron ("Offer Proposal"). Microgen's Offer Proposal was, subject to a number of conditions typical of a transaction of this nature, to make an offer for all of the issued equity of Elektron at a price of 5 pence per share in cash. This would represent:

 

· A value for the existing issued ordinary share capital of Elektron of approximately £6.0 million equivalent to an enterprise value for Elektron, adjusting for net debt at 30 April 2014, of £13.6 million. (The level of investment required under the Offer Proposal (enterprise value of £13.6 million) is similar in value to that of the Refinancing Proposal (£12 million to £18 million), taking into account investment in additional growth opportunities.)

 

· A premium of approximately 17.6% to the mid-market closing share price of 4.25 pence per Elektron share on 16 June 2014

 

Whilst Microgen's Offer Proposal would have sought to acquire 100% of the issued Elektron shares, any offer would have been declared unconditional as to acceptances once Microgen had received valid acceptances and/or acquired voting share rights representing in excess of 75% of the issued Elektron shares. Microgen's offer would have been funded from Microgen's existing cash resources. The Board of Elektron rejected Microgen's Offer Proposal on 13 June 2014 and did not express any interest in reconsidering Microgen's Refinancing Proposal.

 

Microgen considers that its Offer Proposal reflected fair, and arguably generous, value for Elektron shareholders. However, without a recommendation from the Board of Elektron, Microgen confirms that it is inappropriate to proceed with its Offer Proposal at the present time and therefore Microgen does not intend to make an offer for Elektron. Similarly Microgen cannot proceed with its Refinancing Proposal without the support of the Elektron Board.

 

Microgen stated in its announcement of 20 May 2014 that the Refinancing Proposal, with its investment in the £12 million to £18 million range, "offered Elektron shareholders the opportunity to share in the Elektron recovery from a stable financial platform." Microgen also stated in its announcement of 20 May 2014 that "In view of the cash resources absorbed by Elektron in recent years, the continuing deterioration of Elektron's financial position and the proven inability of Elektron to forecast future business prospects, should Elektron receive only a limited cash injection, this may only provide short-term relief and may not provide the confidence required with non-equity stakeholders (customers, suppliers, banks, employees) to enable Elektron to rebuild". It is therefore disappointing that the Board of Elektron have decided not to progress either of the Microgen proposals.

 

Under Rule 2.8 of the Code, and except with the consent of the Panel, the statement that Microgen does not intend to make an offer for Elektron will prevent Microgen, or anyone acting in concert with it (or any person who is subsequently acting in concert with it or them), from announcing an offer or possible offer for Elektron or taking certain other action within the next six months unless there is, in the opinion of the Panel, a material change of circumstances or there has occurred an event which is specified in Note 2 of Rule 2.8 as enabling this statement to be set aside. Accordingly, for the purposes of Rule 2.8, Microgen reserves the right (on behalf of itself and anyone acting in concert with it) to announce an offer or possible offer for Elektron and/or to take any other action which would otherwise be restricted under Rule 2.8 within the next six months in circumstances set out in Note 2 of Rule 2.8.

 

 

Contacts

Martyn Ratcliffe, Chairman 020-7496-8100

Philip Wood, Group Finance Director

 

Lucy Delaney, FTI Consulting 020-3727-1131

 

Rowena Murray, Investec Bank plc 020-7597-5970

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRXQLLFZQFLBBL
Date   Source Headline
10th Aug 20237:00 amRNSTrading update notice of results & contract
8th Jun 20234:08 pmRNSResult of AGM
24th May 20233:29 pmRNSDirector/PDMR Shareholding
15th May 20231:04 pmRNSPosting of Annual Report and Notice of AGM
24th Apr 20237:00 amRNSPreliminary Results
13th Apr 20231:36 pmRNSNotice of Results and Investor Presentation
23rd Mar 20235:25 pmRNSDirector/PDMR Shareholding
13th Mar 20238:55 amRNSStatement re. Silicon Valley Bank
16th Feb 20237:00 amRNSTrading Update and Notice of Results
26th Jan 20234:10 pmRNSDirectorate Change
23rd Jan 20237:00 amRNSDirector/PCA Dealing
10th Jan 20237:00 amRNSAppointment of Non-Executive Director
10th Jan 20237:00 amRNSGrant of options and PDMR dealings
5th Jan 20237:00 amRNSContract wins and investor presentation
12th Dec 20225:14 pmRNSDirector/PDMR Shareholding
27th Sep 202212:28 pmRNSHolding(s) in Company
23rd Sep 20226:16 pmRNSDirector/PDMR Shareholding
16th Sep 20225:36 pmRNSDirector Dealing
15th Sep 20227:00 amRNSInterim Results
6th Sep 20227:00 amRNSInvestor Presentation
22nd Aug 20221:07 pmRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSTrading Update and Notice of Interim Results
9th Jun 20223:09 pmRNSResult of AGM
13th May 20225:17 pmRNSPosting of Annual Report and Notice of AGM
13th May 20227:00 amRNSInvestor Conference
4th May 20227:00 amRNSContract Renewal
28th Apr 20227:00 amRNSPreliminary Results
29th Mar 20227:00 amRNSGrant of options and PDMR dealings
23rd Feb 20227:00 amRNSPDMR Dealing
22nd Feb 20227:00 amRNSPDMR Dealing
17th Feb 20227:00 amRNSTrading update
1st Feb 20227:00 amRNSContract win
22nd Dec 20212:06 pmRNSHolding(s) in Company
20th Dec 20217:01 amEQSCheckit (CKT): SaaS software for the deskless workforce
17th Dec 20212:44 pmRNSDirector/PDMR Shareholding
16th Dec 202111:52 amRNSResult of General Meeting and Admission
2nd Dec 202111:00 amRNSHolding(s) in Company
2nd Dec 202111:00 amRNSHolding(s) in Company
29th Nov 202111:44 amRNSPosting of Circular and Notice of General Meeting
26th Nov 20212:23 pmRNSResult of Placing
26th Nov 20217:00 amRNSProposed Placing
28th Oct 20217:00 amRNSContract win
16th Sep 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSTrading Update and Notice of Interim Results
6th Aug 20213:13 pmRNSDirector/PDMR Shareholding
15th Jul 20217:00 amRNSProduct Update
13th Jul 20215:08 pmRNSGrant of options and PDMR dealings
12th Jul 20217:00 amRNSAppointment of Chief Executive Officer
29th Jun 20214:01 pmRNSCapital Markets Day
10th Jun 20219:16 amRNSPDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.